New Challenges in Heart Failure: An Expert Assessment of How Real-World Observations Are Changing Our Practice
Prof Giuseppe Rosano, Dr John Teerlink and Prof Koichiro Kinugawa discuss the rapid clinical benefits of initiating GDMT in HF and the impact of high-intensity care on adherence and mortality (STRONG-HF).
This comprehensive video series has been designed to enhance your understanding of heart failure (HF) management. Through expert discussions, we explore the real-world adoption of novel guideline-directed medical therapies (GDMTs) and their impact on patient care. We also delve into the benefits of natriuretic peptide (NP) testing, highlighting how it aids in more accurate and rapid diagnosis, which can significantly improve patient outcomes. In addition, this series critically examines the limitations of relying solely on left ventricular ejection fraction (LVEF) for HF diagnosis and offers alternative approaches that reflect current clinical practice.
Join us as we bring real-world insights to life, helping you apply the latest evidence to your practice and ultimately improve patient care.
Key Learning Objectives
- Describe current real-world trends on initiation of novel GDMTs in HF
- Review the latest recommendations for diagnosing HF and the benefit of NP testing
- Recall how rapid diagnosis impacts patient outcomes
- Describe the limitations of LVEF in HF diagnosis
Target Audience
- Cardiologists
- Heart Failure Specialists
- Primary Care Physicians
- Nurses
- Pharmacists
More from this programme
Part 1
Current Treatment Observations
Prof Giuseppe Rosano, Dr John Teerlink and Prof Koichiro Kinugawa discuss the rapid clinical benefits of initiating GDMT in HF and the impact of high-intensity care on adherence and mortality (STRONG-HF).
| 1 session | |
| Watch now |
Part 2
Recent Real-World Observations
In this session, Prof Giuseppe Rosano, Dr John Teerlink and Prof Koichiro Kinugawa discuss recent real-world data, describing GDMT practices within 12 months of a HF hospitalisation (EVOLUTION-HF) and highlight the significant risks associated with not initiating GDMT.
| 1 session | |
| Watch now |
Part 3
Delayed Diagnosis in Context
In this session, Prof Giuseppe Rosano, Dr John Teerlink and Prof Koichiro Kinugawa discuss the adoption of a new universal definition of HF to improve early diagnosis, with emphasis on using NPs and highlight the consequences of delayed diagnosis as seen from population-based studies (REVOLUTION-HF) and real-world data.
| 1 session | |
| Watch now |
Part 4
Moving Beyond LVEF
Prof Giuseppe Rosano, Dr John Teerlink and Prof Koichiro Kinugawa begin this session with a critique of the limitations of a LVEF-centric definition of HF, questioning its ability to capture the condition’s dynamic nature and its impact on trial recruitment, and review the need to understand HF phenotypes, before previewing a revised, more inclusive universal definition aimed at advancing diagnosis and research.
| 1 session | |
| Watch now |
Faculty Biographies
Giuseppe Rosano
Consultant Cardiologist and Professor of Cardiology (Hon)
Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.
Prof Rosano's areas of expertise include heart failure, cardiac metabolism, cardiovascular pharmacology and pharmacotherapy, heart disease in women and cardiovascular effects of sex hormones. He has a specific interest in chronic coronary syndromes and in angina with normal coronary arteries.
Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian…
John R Teerlink
Director
Dr John R Teerlink is Director of the Heart Failure Program and of the Clinical Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center in San Francisco, California.
Dr Teerlink graduated from Swarthmore College with Highest Honors in Comparative Religious Studies and Cellular Biology. After receiving his medical degree from Harvard Medical School, he completed an internal medicine residency at the University of California San Francisco (UCSF).
Koichiro Kinugawa
Chairman and Professor of Cardiovascular Medicine and Nephrology
Prof Koichiro Kinugawa is Chairman and Professor of the Department of Cardiovascular Medicine and Nephrology at University of Toyama, Toyama, JP. He also holds the position of Vice President at the university's hospital. His primary research and clinical focus lies in heart failure, with a specialisation in mechanical circulatory support devices and heart transplantation.
Prof Kinugawa graduated from the University of Tokyo in 1988 and received extensive training in affiliated hospitals. He further honed his expertise abroad, studying at UC San Francisco and University of Colorado Health Sciences Center (UCHSC) in Denver until 2002. Upon returning to Japan, Prof Kinugawa began his academic career as an Assistant Professor at the University of Tokyo. By 2010, he had been promoted to Associate Professor, and in 2013, he became a Project Professor in the Advanced Heart Failure Division.